SITE SPECIFIC CALCIUM BLOCKERS: STRUCTURAL REQUIREMENTS
位点特异性钙阻滞剂:结构要求
基本信息
- 批准号:3343664
- 负责人:
- 金额:$ 10.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1984
- 资助国家:美国
- 起止时间:1984-05-01 至 1991-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The long term objective of this proposal is to clarify the relationship
between the molecular conformation and activities of an important group of
cardiovascular drugs known as Ca2+ channel agents. Particular interest
will be focused on the nifedipine family of 1,4-dihydropyridine drugs and
concentrate on two areas: the determination of those features which
distinguish agonists from antagonists, and the elucidation of those
features which are responsible for selective potency in particular
cardiovascular tissues. X-ray diffraction methods will be used to obtain
molecular conformational data for a number of important compounds which are
to include various aryl-substituted analogs of the lactone agonist, CGP 28
392, and tissue selective antagonists related to nitrendipine and
nimodipine. Efforts will be extended to resolve racemic preparations of
the various tissue selective analogs to provide enantiomeric samples which
will be pharmacologically tested to determine the extent of chiral
preference for selective activity. X-ray diffraction methods, employing
anomalous scattering, will be used to determine the absolute configurations
of those tissue selective analogs which show pronounced enantiomeric
specificity. The MM2P molecular mechanics programs will be used to
corroborate the crystallogaphically observed molecular conformations and
resolve whether the non-observance of trans-trans di-esters is the result
of a higher conformational energy or the inability of such conformers to
hydrogen bond to their environment. The crystallographic conformational
data will provide the basis to determine appropriate semi-empirical values
for the parameters used in these calculations, especially those involving
nitrogenous chemical functions.
These proposed studies will augment the information which has become
available in recent years regarding the chirality of the ligand-receptor
interaction and the cycling of receptor-channel gating states.
Crystallographic data obtained from the initial study period strongly
suggest that there are a limited number of plausible ligand-receptor
binding models which describe how these drugs may stabilize either the
active open or inactive closed states of the Ca2+ channel. The proposed
studies will provide answers which will further clarify the nature of this
drug-receptor interaction by delineating the stereochemical characteristics
required of these molecules to activate or inactivate the Ca2+ channel or
enhance particular tissue selective response. This information will aid
the design of more effective drugs.
这项建议的长远目标是澄清
分子构象和一组重要的
心血管药物称为钙通道剂。 特别感兴趣
将重点关注硝苯地平家族的1,4-二氢吡啶类药物,
集中在两个方面:确定那些特征,
区分激动剂和拮抗剂,并阐明这些激动剂和拮抗剂的作用。
特别是负责选择效力的特征
心血管组织 X射线衍射方法将用于获得
一些重要化合物的分子构象数据,
包括内酯激动剂CGP 28的各种芳基取代的类似物
392,以及与尼群地平相关的组织选择性拮抗剂,
尼莫地平。 将努力解决外消旋制剂的
各种组织选择性类似物以提供
将进行重复测试,以确定手性
选择性活动的偏好。 X射线衍射方法,采用
反常散射,将被用来确定绝对配置
这些组织选择性类似物显示出明显的对映体
的特异性 MM 2 P分子力学程序将用于
证实了晶体学观察到的分子构象,
解决不遵守反式-反式二酯是否是
更高的构象能量或这种构象不能
与环境形成氢键。 晶体构象
数据将为确定适当的半经验值提供基础
对于这些计算中使用的参数,特别是涉及
氮的化学功能
这些拟议的研究将增加已成为
近年来关于配体-受体的手性
相互作用和受体通道门控状态的循环。
从最初的研究阶段获得的晶体学数据强烈
表明存在有限数量合理配体-受体
结合模型描述了这些药物如何稳定
Ca 2+通道的主动开放或非主动关闭状态。 拟议
研究将提供答案,这将进一步澄清这一性质,
药物-受体相互作用的立体化学特征
需要这些分子激活或激活Ca 2+通道,或
增强特定组织选择性反应。 这些信息将有助于
设计更有效的药物。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Direct methods: the identification of conditions which simplify the generation of inconsistent quadrupoles.
直接方法:识别简化不一致四极杆生成的条件。
- DOI:10.1107/s0108767388003435
- 发表时间:1988
- 期刊:
- 影响因子:0
- 作者:Langs,DA;Han,F
- 通讯作者:Han,F
Direct methods: the identification of space-group-specific inconsistent three-phase structure invariants.
直接方法:识别空间群特定的不一致三相结构不变量。
- DOI:10.1107/s010876738800306x
- 发表时间:1988
- 期刊:
- 影响因子:0
- 作者:Han,F;Langs,DA
- 通讯作者:Langs,DA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID A LANGS其他文献
DAVID A LANGS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID A LANGS', 18)}}的其他基金
NEW ALGORITHMS FOR INTRACTABLE DIRECT METHODS PROBLEMS
解决棘手的直接方法问题的新算法
- 批准号:
6301749 - 财政年份:2000
- 资助金额:
$ 10.62万 - 项目类别:
NEW ALGORITHMS FOR INTRACTABLE DIRECT METHODS PROBLEMS
解决棘手的直接方法问题的新算法
- 批准号:
6107595 - 财政年份:1999
- 资助金额:
$ 10.62万 - 项目类别:
NEW ALGORITHMS FOR INTRACTABLE DIRECT METHODS PROBLEMS
解决棘手的直接方法问题的新算法
- 批准号:
6271770 - 财政年份:1998
- 资助金额:
$ 10.62万 - 项目类别:
NEW ALGORITHMS FOR INTRACTABLE DIRECT METHODS PROBLEMS
解决棘手的直接方法问题的新算法
- 批准号:
6240502 - 财政年份:1997
- 资助金额:
$ 10.62万 - 项目类别:
SITE SPECIFIC CALCIUM BLOCKERS: STRUCTURAL REQUIREMENTS
位点特异性钙阻滞剂:结构要求
- 批准号:
3343661 - 财政年份:1984
- 资助金额:
$ 10.62万 - 项目类别:
SITE SPECIFIC CALCIUM BLOCKERS: STRUCTURAL REQUIREMENTS
位点特异性钙阻滞剂:结构要求
- 批准号:
3343659 - 财政年份:1984
- 资助金额:
$ 10.62万 - 项目类别:
SITE SPECIFIC CALCIUM BLOCKERS: STRUCTURAL REQUIREMENTS
位点特异性钙阻滞剂:结构要求
- 批准号:
3343663 - 财政年份:1984
- 资助金额:
$ 10.62万 - 项目类别:
SITE SPECIFIC CALCIUM BLOCKERS: STRUCTURAL REQUIREMENTS
位点特异性钙阻滞剂:结构要求
- 批准号:
3343662 - 财政年份:1984
- 资助金额:
$ 10.62万 - 项目类别:
NEW ALGORITHMS FOR INTRACTABLE DIRECT METHODS PROBLEMS
解决棘手的直接方法问题的新算法
- 批准号:
5212172 - 财政年份:
- 资助金额:
$ 10.62万 - 项目类别:
相似海外基金
Design and Preclinical Development of First-in-Class Selective T-type Calcium Channel Blockers for Chronic Pain
用于治疗慢性疼痛的一流选择性 T 型钙通道阻滞剂的设计和临床前开发
- 批准号:
452107 - 财政年份:2021
- 资助金额:
$ 10.62万 - 项目类别:
Operating Grants
Calcium channel blockers and diuretics: A retrospective cohort study exploring a common prescribing cascade in older adults
钙通道阻滞剂和利尿剂:一项回顾性队列研究,探讨老年人常见的处方级联反应
- 批准号:
400471 - 财政年份:2019
- 资助金额:
$ 10.62万 - 项目类别:
Use of Calcium Channel Blockers to Prevent Prostate Cancer Metastases: Impact on Survival
使用钙通道阻滞剂预防前列腺癌转移:对生存的影响
- 批准号:
264720 - 财政年份:2012
- 资助金额:
$ 10.62万 - 项目类别:
Fellowship Programs
Use of Calcium Channel Blockers to Prevent Prostate Cancer Metastases: Impact on Survival
使用钙通道阻滞剂预防前列腺癌转移:对生存的影响
- 批准号:
254719 - 财政年份:2012
- 资助金额:
$ 10.62万 - 项目类别:
Fellowship Programs
The effects of calcium channel blockers on chick embryo ventricular aggregates
钙通道阻滞剂对鸡胚心室聚集体的影响
- 批准号:
414740-2011 - 财政年份:2011
- 资助金额:
$ 10.62万 - 项目类别:
University Undergraduate Student Research Awards
Expression and characterization of novel L-type calcium channel blockers
新型L型钙通道阻滞剂的表达和表征
- 批准号:
399827-2010 - 财政年份:2010
- 资助金额:
$ 10.62万 - 项目类别:
University Undergraduate Student Research Awards
Application of new catalytic technologies in the synthesis of substituted piperazines. New approaches for the synthesis of calcium channel blockers for pain treatment.
新型催化技术在取代哌嗪合成中的应用
- 批准号:
365198-2008 - 财政年份:2010
- 资助金额:
$ 10.62万 - 项目类别:
Strategic Projects - Group
Effect of the intake of grapefruit juice on blood pressures in hypertensive patients treated with calcium channel blockers
摄入柚子汁对接受钙通道阻滞剂治疗的高血压患者血压的影响
- 批准号:
21590171 - 财政年份:2009
- 资助金额:
$ 10.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Quantitative analysis of the open-state affinity of L-type calcium channel blockers and modeling of their inhibitory actions
L 型钙通道阻滞剂开放态亲和力的定量分析及其抑制作用的建模
- 批准号:
21590275 - 财政年份:2009
- 资助金额:
$ 10.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Expression and characterization of novel L-type calcium channel blockers.
新型 L 型钙通道阻滞剂的表达和表征。
- 批准号:
382808-2009 - 财政年份:2009
- 资助金额:
$ 10.62万 - 项目类别:
University Undergraduate Student Research Awards